Register now

19 March 08:15-09:00Umeå Biotech Incubator, Conference room "Skogen"

Welcome to a UBI House breakfast & seminar at Tvistevägen 48, in conference room "Skogen".

About the seminar: The seminar will discuss what is needed to succeed in the challenging field of new drug development targeting drug-resistant bacterial infections.

Speaker: Markus Thor, CEO of QureTech Bio. 
Has 30 years of experience in the pharma/biotech industry and roles within R&D, business development, and executive leadership. Previous positions include VP & Head of Business Development at Biovitrum, Chief Business Officer at Kancera, and Chief Business Officer at XNK Therapeutics. Markus has a M.Sc. in Chemistry from University of Umeå and an MBA from Stockholm School of Economics.

Registration deadline: Thursday, March 14. After this, you can sign up for the seminar, but not for breakfast. 

NOTE: The event is open to everyone. UBI offers breakfast from 8.15. The seminar starts at 8.30.

Participation fee: This event is sponsored by Umeå Biotech Incubator (UBI) with support from the European Union. There is no actual fee for participating. For delegates from the industry, state-aid/de-minimis will be accounted for corresponding to 50 SEK per person.

State aid & de-minimis: Umeå Biotech Incubator is obliged to account for activities they arrange, and support they provide, that are directed to specific companies or a group of companies where the receiving companies do not pay market price for the participation. The value of this support is accounted for as state-aid. 
Small amounts of State aid (‘de minimis’ aid) are exempted from State aid control, as they are deemed to have no impact on competition and trade in the internal market of the European Union (EU). De minimis aid indeed refers to small amounts of State aid to undertakings (companies) that do not have to be notified to the European Commission by the EU Member States.
The maximum amount is € 300,000 for each undertaking over 3 years.
De minimis can also be granted to large companies that are not entitled to larger sums of state-aid under Article 22. 

Read more on state-aid and de-minimis here:

Register now
© MapTiler © OpenStreetMap contributors

Organized by